Treatment outcome of patients with smear-negative and smear-positive pulmonary tuberculosis in the National Tuberculosis Control Programme, Malawi

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 93, Issue 4, 1999, Pages 443-446

  Harries, A D ^a,c   Nyirenda, T E ^a   Banerjee, A ^a   Boeree, M J ^a,b   Salaniponi, F M L ^a  

^a National Tuberculosis Control Programme Malawi   (Malawi)

^b UNIVERSITY OF MALAWI   (Malawi)

^c British High Commission Lilongwe   (Malawi)

Author keywords

Chemotherapy; Malawi; Smear negative pulmonary tuberculosis; Smear positivity; Treatment outcome; Tuberculosis

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; HEALTH CARE QUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALAWI; MALE; MEDICAL PERSONNEL; MEDICAL RECORD; MORTALITY; SPUTUM SMEAR; TREATMENT OUTCOME; TUBERCULOSIS CONTROL;

EID: 0032837584     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-9203(99)90153-0     Document Type: Article

References (16)

1. Ackah, A. N., Coulibaly, D., Digbeu, H., Diallo, K., Vetter, K. M., Coulibaly, I. M., Greenberg, A. E. & De Cock, K. M. (1995). Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'Ivoire. Lancet, 345, 607-610.
2. Briggs, I. L., Rochester, W. R., Shennan, D. H., Riddell, R. W., Fox, W. F., Heffernan, J. F., Miller, A. B., Nunn, A. J., Stott, H. & Tall, R. (1968). Streptomycin plus thiacetazone (thioacetazone) compared with streptomycin plus PAS and with isoniazid plus thiacetazone in the treatment of pulmonary tuberculosis in Rhodesia. Tubercle, 49, 48-69.
3. De Cock, K. M., Soro, B., Coulibaly, I. M. & Lucas, S. B. (1992). Tuberculosis and HIV infection in sub-Saharan Africa. Journal of the American Medical Association, 268, 1581-1587.
4. East African/British Medical Research Council (1973). Isoniazid with thiacetazone (thioacetazone) in the treatment of pulmonary tuberculosis in East Africa. Tubercle, 54, 169-179.
5. Elliott, A. M., Halwiindi, B. Hayes, R. J., Luo, N., Mwinga, A. G., Tembo, G., Machiels, L., Steenbergen, G., Pobee, J. O. M., Nunn, P. & McAdam, K. P. W. J. (1995) The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia. Transactions of the Royal Society of Tropical Medicine and Hygiene, 89, 78-82.
6. Enarson, D. A., Rieder, H. L., Arnadottir, T. & Trebucq, A. (1996). Tuberculosis Guide for Low Income Countries, 4th edition. Paris: International Union against Tuberculosis and Lung Disease.
7. Gilks, C.F., Brindle, R. J., Otieno, L. S., Simani, P. M., Newnham, R. S., Bhatt, S. M., Lule, G. N., Okelo, G. B. A., Watkins, W. M., Waiyaki, P. G., Were, J. B. O. & Warrell, D. A. (1990). Life threatening bacteraemia in HIV-1-sero-positive adults admitted to hospital in Nairobi, Kenya. Lancet, 336, 545-549.
8. Grzybowski, S., Barnett, G. D. & Styblo, K. (1975). Contacts of cases of active pulmonary tuberculosis. Bulletin of the International Union Against Tuberculosis, 50, 90-106.
9. Harries, A. D., Parry, C., Nyong'onya Mbewe, L., Graham, S. M., Daley, H. M., Maher, D., Salaniponi, F. M. & Nyangulu, D. S. (1997). The pattern of tuberculosis in Queen Elizabeth Central Hospital, Blantyre, Malawi: 1986-1995. International Journal of Tuberculosis and Lung Disease, 1, 346-351.
10. Harries, A. D., Nyangulu, D. S., Kang'ombe, C., Ndalama, D., Glynn, J. R., Banda, H., Wirima, J. J., Salaniponi, F. M., Liomba, G., Maher, D. & Nunn, P. (1998). Treatment outcome of an unselected cohort of tuberculosis patients in relation to human immunodeficiency virus serostatus in Zomba hospital, Malawi. Transactions of the Royal Society of Tropical Medicine and Hygiene, 92, 343-347.
11. Nunn, P., Kibuga, D., Gathua, S., Brindle, R., Imalingat, A., Wasunna, K., Lucas, S., Gilks, C., Omwega, M., Were, J. & McAdam, K. (1991). Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet, 337, 627-630.
12. Nunn, P., Brindle, R., Carpenter, L., Odhiambo, J., Wasunna, K., Newnham, R., Githui, W., Gathua, S., Omwega, M. & McAdam, K. (1992). Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6-month) mortality. American Review of Respiratory and Critical Care Medicine, 146, 849-854.
13. Nunn, P., Porter, J. & Winstanley, P. (1993). Thiacetazone - avoid like poison or use with care? Transactions of the Royal Society of Tropical Medicine and Hygiene, 87, 578-582.
14. Okwera, A., Whalen, C., Byekwaso, F., Vjecha, M., Johnson, J., Huebner, R., Mugwera, R., Ellner, J. & The Makerere University-Case Western University Research Collaboration (1994). Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. Lancet, 344, 1323-1328.
15. Perriens, J. H., St. Louis, M. E., Mukadi, Y. B., Brown, C., Prignot, J., Pouthier, F., Portaels, F., Willame, J. C., Manadala, J. K., Kaboto, M., Ryder, R. W., Roscigno, G. & Piot, P. (1995). Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. New England Journal of Medicine, 332, 779-784.
16. WHO (1997). Treatment of Tuberculosis: Guidelines for National Programmes, 2nd edition. Geneva: World Health Organization.